Drugs / IV immunoglobulin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05350774 | Jul 2023 → Dec 2026 expected | autoinflammatory syndrome, thrombotic disease | National Institute of Neurological Disorders and Stroke (NINDS) | Enrolling by invitation | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IV immunoglobulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05350774 ↗ |
| Known as | human immunoglobulin | “To learn if human immunoglobulin (IVIG) will help with neurological symptoms of Long COVID.” NCT05350774 ↗ |
| Modality | Protein / enzyme biologic | “human immunoglobulin (IVIG)” NCT05350774 ↗ |
| Route | Intravenous | “IVIg - IV immunoglobulin 0.4g/kg/day for 5 days” NCT05350774 ↗ |